Related Experiment Video
Updated: Jan 18, 2026
Comparison of Three Clinical Stereoscopic Methods for Measuring Binocular Visual Function During Amblyopic Treatment in Unilateral Amblyopia
Published on: September 27, 2024
Selective serotonin reuptake inhibitors for amblyopia treatment: a systematic review and meta-analysis of randomized
Ehtesham Shamsher1, Luisa Saccaro2, Victor Barreiros Pungirum3
1Oxford Eye Hospital, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
Introduction:
Amblyopia is a neurodevelopmental visual disorder treated with occlusion or pharmacological penalization of the dominant, non-amblyopic eye in early childhood. After early childhood, efficacy of occlusion therapy is limited due to a reduction in neuronal plasticity, and no mainstay clinical treatment is available. Selective serotonin reuptake inhibitors (SSRIs) have been hypothesized to enhance neuroplasticity in the adult brain, thereby facilitating improvements in amblyopia. We aimed to perform a systematic review and meta-analysis evaluating the effect of SSRIs on patients with amblyopia.
Methods:
We systematically searched Pubmed, EMBASE, and Cochrane Central for randomized controlled trials (RCTs) and controlled observational studies comparing an SSRI with placebo in patients with amblyopia. Outcomes of interest were visual acuity (VA) change and visual evoked potential (VEP) change (P100 amplitude and latency). Statistical analysis was performed using the web version of RevMan by calculating the mean difference between groups (MD). Heterogeneity was assessed with Cochrane Q test and I2 statistics.
Results:
Four RCTs and 139 patients were included. 55% patients received SSRIs. Three studies used fluoxetine and one study used citalopram as the intervention. While SSRIs use statistically improved VA (MD 0.09 logMAR, 95% CI 0.04-0.14, p = 0.0004), the extent of improvement was not clinically significant. SSRIs did not have any effect on VEPs.
Conclusion:
While SSRIs significantly improved VA in patients, the increase was not clinically significant as it represents less than one line of improvement on the Snellen chart. Given the minimal change in VA, it may be necessary to combine SSRIs with other modalities of intervention to demonstrate a clinically significant effect. Secondary endpoints that capture effects at the level of the retina and the brain would provide knowledge of physiological mechanisms that can improve future therapies.
Systematic Review Registration:
CRD42025633077, https://www.crd.york.ac.uk/PROSPERO/view/CRD42025633077.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment